AlphAIAlphAI — Financial news for AI agents
stocktitan.netSEP 151 min read$VIRC

Virco (VIRC) insider lifts stake to 897,408 shares

Virco Mfg Corporation (VIRC) EVP Douglas Virtue bought 3,000 shares at $6.10 each, increasing his direct holdings to 897,408 shares. The purchase was made in an open-market or private transaction on September 15, 2026, and was not part of a Rule 10b5-1 trading plan.

Original reporting
stocktitan.net
Published Sep 15, 2026, 5:25 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 16, 2026, 8:50 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$VIRC
Neutral
medium confidence
Mentioned
$VIRC
Relevance
4/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$VIRCNeutralLow
01

Why it matters

The purchase adds modest confidence but is unlikely to affect price materially.

02

Market read

A routine insider buy with limited trading relevance.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed in the filing.

Relevance 4/10Novelty 4/10Timing: September 15, 2026 (same‑day filing)

Background

Form 4 filing discloses an insider's open‑market purchase of Virco common stock.

Company-level read

Ticker impact

$VIRCNeutralMedium confidence
Context

Executive Vice President Douglas A. Virtue purchased 3,000 shares of Virco at $6.10, raising his holdings to 897,408 shares.

Expected impact

Minimal upward pressure, unlikely to move the stock materially.

Evidence & confidence

The transaction size is trivial relative to market cap and typical daily volume.

Market effects

Sector

None; Virco operates in the school furniture sector with no broader sector impact.

Regional

None; the trade is localized to the company.

Global

None; the filing does not affect global markets.

Counterpoint

What could challenge this read

Given the tiny size, the purchase may be a routine portfolio rebalancing rather than a confidence signal.

Key entities

  • Company
    Virco Mfg Corporation

    Manufacturer of school furniture, ticker VIRC.

  • Executive
    Douglas A. Virtue

    Executive Vice President and director of Virco.

Read at source← All news

Related articles

SEP 4
$VIRCMed

Virco Reports Revenue through Six Months Declined 6.1% to $118.2 Million from $125.8 Million, as Rebalancing of School Furniture Market Continues

VIRCO MFG CORPORATION (VIRC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Virco Reports Revenue through Six Months Declined 6.1% to $118.2 Million from $125.8 Million, as Rebalancing of School Furniture Market Continues • Operating Income of $10.5 Million for Second Quarter Remains Above Long-Term Average • Shipments Plus Backlog of $162.5

SEC EDGAR 8-K2 min
OCT 23
$MGNXMedAI 8/10

MacroGenics Announces Positive Interim Phase 1 Results for MGC026 and Highlights Plans to Initiate Front-Line Combination Study in SCCHN

MACROGENICS INC (MGNX) filed an SEC Form 8-K — Other Events. MacroGenics Announces Positive Interim Phase 1 Results for MGC026 and Highlights Plans to Initiate Front-Line Combination Study in SCCHN • Durable responses observed across multiple tumor types during dose escalation • MGC026 demonstrated 27% best overall response rate (6/22 pati

SEC EDGAR 8-K2 min
OCT 23
$CPIXMedAI 8/10

Cumberland Pharmaceuticals Announces ASSIST-SSc Trial Top-Line Results

Cumberland Pharmaceuticals (CPIX) reported Phase 2a trial results for ifetroban in systemic sclerosis (SSc) patients. The drug was well-tolerated, with a safety profile consistent with prior studies. The trial was not designed to evaluate efficacy. Cumberland plans to submit results to the FDA and conduct further biomarker studies. SSc is a rare autoimmune disease with limited treatment options for cardiac manifestations.

prnewswire.com2 min
OCT 23
$AVBPMedAI 8/10

First human data on an experimental cancer drug will be presented in a late-breaking session.

ArriVent BioPharma (Nasdaq: AVBP) announced that initial safety and efficacy data from its Phase 1 study of ARR-217, a CDH17-targeted ADC for gastrointestinal cancers, will be presented at ESMO Congress 2026. The company will host a webinar on October 26, 2026, to discuss the data. ARR-217 is ArriVent's lead clinical candidate, obtained via a collaboration with Lepu Biopharma.

stocktitan.net2 min
OCT 23
$MMMHigh

Post-it Notes maker 3M eyes AI gold rush in major Amazon deal

3M (MMM) expanded its deal with Amazon (AMZN) for up to $6B in fiber-optic gear for AI/data centers. 3M shares rose 5% post-announcement. Amazon gets a warrant to buy 3.16M 3M shares at $164.89 each, tied to purchase milestones. 3M also invested in Genius Electronic Optical to scale production. Microsoft (MSFT) is another key partner.

finance.yahoo.com2 min
OCT 23
$ZYMEHighAI 8/10

Jefferies raises Zymeworks stock price target on Roche deal

Jefferies raised its price target on Zymeworks (NASDAQ:ZYME) to $52 from $50, maintaining a Buy rating after its licensing deal with Roche. The deal includes $55M upfront, $40M upon Phase 1b trial initiation, and up to $718M in milestone payments. Zymeworks' stock is currently at $28.30, up 63% over the past year. The company also completed its acquisition of Theravance Biopharma, which could generate over $100M in annual cash flow.

investing.com2 min